Hepion Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
HEPA$0.11-13.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash | $1,497,106 | $14,785,880 |
| Prepaid expenses | 1,433,186 | 2,701,960 |
| Related party receivable | 600,000 | — |
| Total current assets | 3,530,292 | 17,487,840 |
| Property and equipment, net | — | 29,487 |
| Right-of-use assets | 118,301 | 212,878 |
| Other assets | 66,505 | 364,192 |
| Total assets | $3,715,098 | $18,094,397 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $186,259 | $2,348,829 |
| Accrued expenses | 306,000 | 2,439,351 |
| Operating lease liabilities, current | 117,952 | 115,916 |
| Notes payable, current | 2,105,753 | — |
| Short-term portion of contingent consideration | — | 386,000 |
| Total current liabilities | 2,715,964 | 5,290,096 |
| Contingent consideration, non-current | — | 1,634,000 |
| Operating lease liabilities, non-current | — | 93,104 |
| Derivative financial instruments-warrants | 1,405,819 | 3,796,390 |
| Total liabilities | 4,121,783 | 10,813,590 |
| Commitments and contingencies (see Note 12) | - | |
| Stockholders’ equity: | ||
| Series A convertible preferred stock, stated value $10 per share, 85,581 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 855,808 | 855,808 |
| Series C convertible preferred stock, stated value $1,000 per share, 1,688 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 839,320 | 839,320 |
| Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 6,958,371 and 4,818,733 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 663 | 482 |
| Additional paid-in capital | 234,223,707 | 230,291,362 |
| Accumulated other comprehensive loss | (53,831) | (78,779) |
| Accumulated deficit | (236,272,352) | (224,627,386) |
| Total stockholders’ equity | (406,685) | 7,280,807 |
| Total liabilities and stockholders’ equity | $3,715,098 | $18,094,397 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.